Top

International Journal of Clinical Oncology

Published in:

01-02-2014 | Original Article

Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer

Authors: Jin Sakamoto, Makoto Sonobe, Masashi Kobayashi, Masashi Ishikawa, Ryutaro Kikuchi, Daisuke Nakajima, Tetsu Yamada, Ei Nakayama, Tsuyoshi Takahashi, Toshihiko Sato, Fengshi Chen, Toru Bando, Hiroshi Date

Published in: International Journal of Clinical Oncology | Issue 1/2014

Abstract

Background

Postoperative recurrence in non-small cell lung cancer (NSCLC) reduces the life expectancy of patients. In this retrospective study, we investigated the prognostic factors in patients with postoperative brain metastases from surgical resected non-small cell lung cancer (NSCLC).

Methods

We conducted a retrospective chart review of patients who had undergone resection for NSCLC between April 2004 and February 2009 and found 65 had experienced postoperative brain metastases by March 2010. We reviewed these patients for clinicopathological information, treatments and responses to treatment, and overall survival.

Results

The 5-year survival rate after the diagnosis of brain metastases was 15.4 %. Significantly favorable prognostic factors for patients after a diagnosis of brain metastases included female gender, adenocarcinoma, a small number (1–3) of brain metastases, no extracranial metastasis at the diagnosis of brain metastases, radiation treatment (whole-brain radiation and/or stereotactic irradiation), and local treatment [stereotactic irradiation and/or surgical operation (craniotomy)]. Furthermore, in patients with only brain metastases as the postoperative initial recurrence, the favorable positive prognostic factors included a small number (1–3) of brain metastases, adjuvant chemotherapy, chemotherapy (including adjuvant and other chemotherapy and excluding epidermal growth factor receptor–tyrosine kinase inhibitors), and local treatment.

Conclusions

Our study found that the foregoing clinical characteristics in postoperative brain metastases and the administration of treatment contributed to patient life expectancy.

Mintz A, Perry J, Spithoff K et al (2007) Management of single brain metastasis: a practice guideline. Curr Oncol 14:131–143PubMedCentralPubMedCrossRef

Kvale PA, Simoff M, Prakash UB et al (2003) Lung cancer. Palliative care. Chest 123:284S–311SPubMedCrossRef

Mamon HJ, Yeap BY, Janne PA et al (2005) High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23:1530–1537PubMedCrossRef

Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717PubMedCrossRef

Goya T, Asamura H, Yoshimura H et al (2005) Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50:227–234PubMedCrossRef

Ichinose Y, Yano T, Yokoyama H et al (1994) Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 108:158–161PubMed

Williams BA, Sugimura H, Endo C et al (2006) Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 81:1021–1027PubMedCrossRef

Sugimura H, Nichols FC, Yang P et al (2007) Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 83: 409–417; discussion 417–418

Mehta MP, Tsao MN, Whelan TJ et al (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 63:37–46PubMedCrossRef

10.

Burt M, Wronski M, Arbit E et al (1992) Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center thoracic surgical staff. J Thorac Cardiovasc Surg 103: 399–410; discussion 410–411

11.

Kim JE, Lee DH, Choi Y et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65:351–354PubMedCrossRef

12.

Lan KK, Rosenberger WF, Lachin JM (1995) Sequential monitoring of survival data with the Wilcoxon statistic. Biometrics 51:1175–1183PubMedCrossRef

13.

Nakamura H, Ando K, Shinmyo T et al (2011) Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 17:469–480PubMedCrossRef

14.

Batevik R, Grong K, Segadal L et al (2005) The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer 47:173–181PubMedCrossRef

15.

Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533–540PubMedCrossRef

16.

Bradley KA, Mehta MP (2004) Management of brain metastases. Semin Oncol 31:693–701PubMedCrossRef

17.

Shiau CY, Sneed PK, Shu HK et al (1997) Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 37:375–383PubMedCrossRef

18.

Flickinger JC, Kondziolka D, Lunsford LD et al (1994) A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28:797–802PubMedCrossRef

19.

Engenhart R, Kimmig BN, Hover KH et al (1993) Long-term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. Cancer (Phila) 71:1353–1361CrossRef

20.

Adler JR, Cox RS, Kaplan I et al (1992) Stereotactic radiosurgical treatment of brain metastases. J Neurosurg 76:444–449PubMedCrossRef

21.

Mehta MP, Rozental JM, Levin AB et al (1992) Defining the role of radiosurgery in the management of brain metastases. Int J Radiat Oncol Biol Phys 24:619–625PubMedCrossRef

22.

Sneed PK, Suh JH, Goetsch SJ et al (2002) A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53:519–526PubMedCrossRef

23.

Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491PubMedCrossRef

24.

Serizawa T, Saeki N, Higuchi Y et al (2005) Gamma knife surgery for brain metastases: indications for and limitations of a local treatment protocol. Acta Neurochir (Wien) 147: 721–726; discussion 726

25.

Kihlstrom L, Karlsson B, Lindquist C (1993) Gamma Knife surgery for cerebral metastases. Implications for survival based on 16 years experience. Stereotact Funct Neurosurg 61(suppl 1):45–50

26.

Borgelt B, Gelber R, Kramer S et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1–9PubMedCrossRef

27.

Asai A, Matsutani M, Kohno T et al (1989) Subacute brain atrophy after radiation therapy for malignant brain tumor. Cancer (Phila) 63:1962–1974CrossRef

28.

DeAngelis LM, Delattre JY, Posner JB (1989) Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789–796PubMedCrossRef

29.

Kelly K, Bunn PA Jr (1998) Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 20:85–91PubMedCrossRef

30.

Rubins J, Unger M, Colice GL et al (2007) Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132:355S–367SPubMedCrossRef

31.

Alberts WM (2007) Follow up and surveillance of the patient with lung cancer: what do you do after surgery? Respirology 12:16–21PubMedCrossRef

32.

Cotto C, Berille J, Souquet PJ et al (1996) A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 32A:69–71PubMedCrossRef

33.

Furuse K, Kamimori T, Kawahara M et al (1997) A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis. Br J Cancer 75:614–618PubMedCentralPubMedCrossRef

Title: Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer
Authors: Jin Sakamoto
Makoto Sonobe
Masashi Kobayashi
Masashi Ishikawa
Ryutaro Kikuchi
Daisuke Nakajima
Tetsu Yamada
Ei Nakayama
Tsuyoshi Takahashi
Toshihiko Sato
Fengshi Chen
Toru Bando
Hiroshi Date
Publication date: 01-02-2014
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0503-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment

Clinical outcomes of urothelial carcinoma of the prostate detected in radical cystectomy specimens

Chronological shifts and changing causes of death after radiotherapy for early-stage oral cancer

Safe lumbar puncture under analgo-sedation in children with acute lymphoblastic leukemia

Fibromyalgia and breast cancer

Dominant lymph drainage in the upper extremity and upper trunk region: evaluation of lymph drainage in patients with skin melanomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer